PTCL Therapeutic Pipeline Reviewed by Global Markets Direct in Topical Study Now Available at MarketPublishers.com12 Sep 2013 • by Natalie Aster
LONDON – Peripheral T-cell lymphomas (PTCLs), a subdivision of T-cell non-Hodgkin lymphomas (NHL) and distinct from the more common cutaneous T-cell lymphomas, are a diverse group of disorders that are usually associated with poor outcome. PTCLs collectively account for about 10% to 15% of all NHL cases in the United States. Studies that focus specifically on PTCL are emerging, with the ultimate target being to enhance understanding of disease biology and establish more effective, less toxic therapies.
Clinical trials are key to identifying effective drugs and determining optimal doses for lymphoma patients. Many new drugs are being studied in clinical trials for the treatment of PTCL, including Alisertib (MLN8237), Alemtuzumab (Campath), Bortezomib (Velcade), Vorinostat (Zolinza), E7777, Dasatinib (Sprycel), Lenalidomide (Revlimid), Panobinostat (LBH-589), Romidepsin (Istodax), etc. Companies involved in PTCL therapeutics development encompass Kyowa Hakko Kirin Co., Ltd., Millennium Pharmaceuticals, Inc., Eisai Co., Ltd., Celgene Corporation, TopoTarget A/S, Mundipharma International Limited, and Chipscreen Biosciences Ltd, among others.
Topical study “Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2013” developed by Global Markets Direct provides a complete overview of the global therapeutic development for PTCL. It reviews the PTCL products under development by companies and universities/research institutes; covers the PTCL products based on various stages of development ranging from discovery till registration stages; features pipeline projects based on monotherapy and combined therapeutics; examines the PTCL pipeline on the basis of route of administration and molecule type; give insight on key discontinued pipeline projects. The research also offers valuable information on the companies involved in PTCL therapeutics development, identifying the emerging players with potentially strong product portfolio. Furthermore, the report is supplemented with the latest news and deals relating to the products.
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2013
Published: July, 2013
Price: US$ 2,000.00
Other Diseases Therapeutic Pipeline Reviews H2 2013 by Global Markets Direct Include:
- Small-Cell Lung Cancer - Pipeline Review, H2 2013
- Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2013
- Toxic Shock - Pipeline Review, H2 2013
- Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2013
- Neurofibromatoses Type II - Pipeline Review, H2 2013
More studies by the publisher can be found at Global Markets Direct page.